English (UK)
中文版Bridge Point Capital 
We are a cross-border private equity fund dedicated to actively pursuing primarily late stage U.S healthcare companies that will benefit from penetrating the vast Asian healthcare market. We identify the well-managed western companies with advanced technology or systems to disrupt the global healthcare market, especially the ones with great market potential in Asia.
Miss Nadia Tian
Founding PartnerBRIMED PHARMA GROUP 
Founded in Wuxi, 2017
Focus on development, manufacturing and marketing of drugs
Registered capital is RMB 280M
Consists of Wuxi Fortune, Qingzhipin Pharma and Sihuan Pharma
Annual revenues - RMB 1 billion (~0.5 billion for antibiotics)
To be public company within 5 years in China
Focus on development, manufacturing and marketing of drugs
Registered capital is RMB 280M
Consists of Wuxi Fortune, Qingzhipin Pharma and Sihuan Pharma
Annual revenues - RMB 1 billion (~0.5 billion for antibiotics)
To be public company within 5 years in China
Fangyue Zou
Planning SpecialistButton Capital
An investment firm focused on early-stage Biotech and MedTech startups.
Responsive Web Design powered by 